Indonesia’s pharmaceutical industry, the largest in ASEAN, is projected to reach a market value of USD 11 billion by 2025. However, heavy reliance on imported raw materials, high drug prices and limited R&D capacity remain critical challenges. In response, the Indonesian government is implementing key reforms: 100% foreign ownership now permitted in the pharmaceutical sector. Focus on local production of raw materials and active pharmaceutical ingredients (API). Encouragement of strategic partnerships with overseas firms. The growing demand, fuelled by national healthcare expansion and an ageing population, presents significant investment opportunities for foreign companies in local manufacturing, OEM partnerships, technology collaborations for raw materials & API production and export of pharmaceutical ingredients Subscribe to Asian Insiders for expert insights on Asia’s biggest opportunities!